Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist